Showing 3041-3050 of 3223 results for "".
- States Bring Price Fixing Suit Against Generic Drug Makershttps://modernod.com/news/states-bring-price-fixing-suit-against-generic-drug-makers/2476576/Attorneys general from more than 40 states are alleging the nation’s largest generic drug manufacturers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs, including treatments for diabetes, cancer, arthritis, and other medical conditions, acco
- HHS Finalizes Rule Requiring Manufacturers Disclose Drug Prices in TV Ads to Increase Drug Pricing Transparencyhttps://modernod.com/news/hhs-finalizes-rule-requiring-manufacturers-disclose-drug-prices-in-tv-ads-to-increase-drug-pricing-transparency/2476569/On Wednesday, Health and Human Services Secretary Alex Azar announced a final rule from the Centers for Medicare & Medicaid Servi
- Genentech: Pivotal Phase 3 Data for Neuromyelitis Optica Spectrum Disorder (Devic’s Disease)https://modernod.com/news/genentech-pivotal-phase-3-data-for-neuromyelitis-optica-spectrum-disorder-devics-disease/2476566/Genentech presented new pivotal phase 3 data for the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), also known as Devic’s Disease, for which there are no approved treatments. NMOSD is a rare, lifelong and debilitating autoimmune disease of the c
- Schwind Introduces WiseNET Intelligent Web-Based Databasehttps://modernod.com/news/schwind-introduces-wisenet-intelligent-web-based-database/2476554/Schwind WiseNET is a web-based database that allows the user to capture and evaluate refractive treatment data quickly and precisely, and present it graphically for all sorts of uses in daily clinical work. Diagrams s
- Biotech Healthcare Announces Korean Good and Manufacturing Practices Approvalhttps://modernod.com/news/biotech-healthcare-announces-korean-good-and-manufacturing-practices-approval/2476544/Biotech Healthcare has received KGMP (Korean Goods & Manufacturing Practice) approval, allowing its ophthalmic products to be accessible to South Korean markets. “Today when we talk about addressing the urgent need of global eye care problems, may that be cataracts or the myopic wave t
- Lensar Laser System Receives FDA Clearance to Perform Micro Radial Incisions for Refractive Cataract Procedureshttps://modernod.com/news/lensar-laser-system-receives-fda-clearance-to-perform-micro-radial-incisions-for-refractive-cataract-procedures/2476537/Lensar announced it received 510(k) clearance from the FDA for the Lensar Laser System with Streamline IV, expanding the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post cataract surgery. “This indicat
- New President/CEO at The Glaucoma Foundationhttps://modernod.com/news/new-president-ceo-at-the-glaucoma-foundation/2476529/The Board of Directors of The Glaucoma Foundation (TGF) has announced the appointment of Elena Sturman as President and Chief Executive Officer, following the retirement of Scott R. Christensen, who held the position since 2002. She wi
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- Bausch + Lomb Announces Update From Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) Studyhttps://modernod.com/news/bausch-lomb-announces-update-from-antibiotic-resistance-monitoring-in-ocular-microorganism-armor-study/2476512/Bausch + Lomb announced the results from nearly 10 years of the ARMOR (Antibiotic Resistance Monitoring in Ocular Microorganisms) surveillance study, presented at the ARVO meeting in Vancouver. Researchers also presented preliminary 2018 surveillance data on antibiotic resistance levels. Initiate
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr